BioSpace News Archive

The Society for Vascular Surgery® Vascular Quality Initiative® (SVS VQI) has recently surpassed 700 participating medical centers and 700,000 procedures.

DURECT Corporation (Nasdaq: DRRX) today announced it has dosed the first patient in its randomized, double-blind, placebo-controlled, multi-center Phase 2 study to evaluate the safety and efficacy of DUR-928 in hospitalized COVID-19 patients with acute liver or kidney injury. The primary efficacy endpoint is a composite of

Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that the inactivated COVID-19 vaccine candidate developed by Sinovac Life Sciences (Sinovac LS), or “CoronaVac”, was approved by the National Medical Products Administration (NMPA) for clinical trial in adolescents and children in August 10 th , 2020. This randomized, double-blinded, an

Nautilus Medical Technologies has just announced an advanced all-in-one surgery recorder, named TeleRay Record, for use with any endoscope, headset, c-arm, vascular, ultrasound, c-arms, and more.

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to the Company’s supplemental New Drug Application(sNDA)for XALKORI® (crizotinib) for the treatment of pediatric patients with relapsed or refractory systemic anaplastic

Swedish Orphan Biovitrum AB and Selecta Biosciences, Inc. announced the commencement of the phase 3 clinical programme of SEL-212 for chronic refractory gout, with the randomisation of the first patient in the study.

vTv Therapeutics Inc. (Nasdaq: VTVT) yesterday presented data from the completed Phase 2 Simplici-T1 study ( NCT03335371 ) that support the clinical potential of TTP399 as an oral adjunctive therapy in type 1 diabetes (T1D). Newly reported data provide additional evidence suggesting that TTP399 does not increase the risk of diabetic ketoacidosis (DKA), a serious and potentially life-threatening complication that occurs in patients with T1D

BioVie Inc. (NASDAQ:BIVI) (“BioVie” or “Company”), a clinical-stage company developing innovative drug therapies for liver disease, today announced that it has closed its previously announced underwritten public offering of Class A common stock, including the full exercise of the underwriters’ overallotment option, resulting in aggregate gross proceeds to the Company of $18.0 million. The Class A common stock sold in the offering has bee

Thermo Fisher Scientific today introduced the Oncomine Clinical Research Grant Program to support clinical research projects in oncology and reproductive health. The program aims to provide support for high-quality molecular profiling studies focused on the generation of data that may improve clinical outcomes for patients

Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that clinical data for ILUVIEN ® (fluocinolone acetonide intravitreal implant) 0.19mg will be featured in over 20 papers and presentations during the EURETINA 2020 Virtual Congress, to be held on October 2-4, 2020. Key presentations include data supporting the